For the integrated multidisciplinary approach to patient care

Return to the Southern Medical Journal

Current User S2 Access Level: -1 ()
CAN NOT ACCESS LEVEL 2
Review Article

Clinical Utility of Natriuretic Peptides in Left Ventricular Failure

Pramod Reddy, MD, Rohan Samson, MD
Volume: 106 Issue: 2 February, 2013

Abstract:

Left ventricular failure (LVF) is a clinical syndrome caused by abnormal systolic or diastolic function failing to meet the metabolic requirements of the body. It is important to diagnose and manage LVF in the earliest stages to prevent mortality and morbidity. This article extensively reviews the diagnostic, therapeutic, and prognostic utility of natriuretic peptides in LVF.

Article:

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

Images:

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

References:

1. Hebert K, Horswell R, Heidenreich P, et al. Handheld ultrasound, B-natriuretic peptide for screening stage B heart failure. South Med J 2010; 103: 616–622.
 
2. Nagueh SF, Appleton CP, Gillebert TC. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107–133.
 
3. Kasner M, Westermann D, Steendijk P. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007; 116: 637–647.
 
4. Clerico A, Zucchelli C, Pilo G, et al. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and N terminal-proBNP assay. Clin Chem Lab Med 2006; 44: 366–378.
 
5. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001; 37: 1221–1227.
 
6. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97: 4239–4244.
 
7. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003; 108: 13–16.
 
8. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.Heart 2003; 89: 745–751.
 
9. Redfield MM, Rodeheffer RJ, Jacobsen SJ. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982.
 
10. Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46: 124–129.
 
11. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47: 85–90.
 
12. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004; 164: 2247–2252.
 
13. Hunt PJ, Richards AM, Nicholls MG. Immunoreactive amino-terminal pro-brain natriuretic peptide (N terminal-Pro BNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287–296.
 
14. Biosite Incorporated 9975 Summers Ridge Road San Diego, California 92121.
 
15. Roche Diagnostics, Indianapolis, IN 46256-1045.
 
16. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–167.
 
17. O’Donoghue M, Chen A, Baggish AL, et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 2005; 11 (5 Suppl): S9–S14.
 
18. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47: 91–97.
 
19. Tang WH, Girod JP, Lee MJ, et al. Plasma B- type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108: 2964–2966.
 
20. Khan IA, Fink J, Nass C, et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530–1534.
 
21. Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420–428.
 
22. Tapolyai M, Uysal A, Maeweathers G, et al. B-type natriuretic peptide-directed ultrafiltration improves care in acutely hospitalized dialysis patients. Congest Heart Fail 2009; 15: 131–135.
 
23. Liu H, Zhang YZ, Gao M, et al. Elevation of B-type natriuretic peptide is a sensitive marker of left ventricular diastolic dysfunction in patients with maintenance haemodialysis. Biomarkers 2010; 15: 533–537.
 
24. Osajima A, Okazaki M, Tamura M, et al. Comparison of plasma levels of mature adrenomedullin and natriuretic peptide as markers of cardiac function in hemodialysis patients with coronary artery disease. Nephron 2002; 92: 832–839.
 
25. Guglin M, Hourani R, Pitta S. Factors determining extreme brain natriuretic peptide elevation. Congest Heart Fail 2007; 13: 136–141.
 
26. Wahl HG, Graf S, Renz H, et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071–1074.
 
27. Flemmer M, Rajab H, Mathena T, et al. Blood B-type natriuretic peptide and dialysis: present assessment and future analyses. South Med J 2008; 101: 1094–1100.
 
28. Pieralli F, Olivotto I, Vanni S, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97: 1386–1390.
 
29. Lega JC, Lacasse Y, Lakhal L, et al. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64: 869–875.
 
30. Ohigashi H, Haraguchi G, Yoshikawa S, et al. Comparison of biomarkers for predicting disease severity and long-term respiratory prognosis in patients with acute pulmonary embolism. Int Heart J2010; 51: 416–420.
 
31. Kostrubiec M, Pruszczyk P, Bochowicz A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166–2172.
 
32. Wang L, Geng J, Li T, et al. The biomarker N-terminal pro-brain natriuretic peptide and liver diseases. Clin Invest Med 2011; 34: E30–E37.
 
33. Pimenta J, Paulo C, Gomes A, et al. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010; 30: 1059–1066.
 
34. Padillo J, Rioja P, Munoz-Villanueva MC, et al. BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 1331–1336.
 
35. Hartemink KJ, Twisk JW, Groeneveld AB. High circulating N-terminal pro-B-type natriuretic peptide is associated with greater systolic cardiac dysfunction and nonresponsiveness to fluids in septic vs nonseptic critically ill patients. J Crit Care 2011; 26: 108.e1–8.
 
36. Ambrosi P, Singeorzan S, Oddoze C, et al. Correlation of N terminal-proBNP with diastolic left ventricular function in elderly patients with ischemic stroke. Int J Cardiol 2010; 140: 126–128.
 
37. Solus J, Chung CP, Oeser A, et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2662–2669.
 
38. Pakuła D, Marek B, Kajdaniuk D, et al. Plasma levels of N terminal-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol 2011; 62: 523–528.
 
39. Antonelli A, Ferri C, Ferrari SM, et al. N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with hepatitis C. J Interferon Cytokine Res 2010; 30: 359–363.
 
40. Kucukazman M, Ata N, Yavuz B, et al. Elevation of B-type natriuretic peptide level in asymptomatic hepatitis B virus-positive patients is not associated with abnormalities of cardiac function. Med Princ Pract 2012; 21: 150–155.
 
41. Logeart D, Thabut G, Jourdain P. Predischarge B- type natriuretic peptide after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641.
 
42. Maeda K, Tsutamoto T, Wada A. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587–1593.
 
43. Svensson M, Gorst-Rasmussen A, Schmidt EB. N terminal-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol 2009; 7: 380–386.
 
44. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47: 552–558.
 
45. Shibazaki K, Kimura K, Okada Y, et al. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 2009; 48: 1601–1606.
 
46. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294: 2866–2871.
 
47. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–663.
 
48. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609–1616.
 
49. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184–3189.
 
50. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246–253.
 
51. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487–1491.
 
52. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32–43.

CME:

Portions of this issue may be available for CME credit. Please email education@sma.org for a complete listing of current Southern Medical Journal activities, as well as other SMA educational offerings.

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

Permissions